CN112584858A - 抗原性ospa多肽 - Google Patents

抗原性ospa多肽 Download PDF

Info

Publication number
CN112584858A
CN112584858A CN201980035045.3A CN201980035045A CN112584858A CN 112584858 A CN112584858 A CN 112584858A CN 201980035045 A CN201980035045 A CN 201980035045A CN 112584858 A CN112584858 A CN 112584858A
Authority
CN
China
Prior art keywords
lys
ospa
glu
leu
ser
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980035045.3A
Other languages
English (en)
Chinese (zh)
Inventor
G·J·纳贝尔
C-J·魏
H·坎普
R·魏
K·斯旺森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Original Assignee
Sanofi Aventis France
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis France filed Critical Sanofi Aventis France
Publication of CN112584858A publication Critical patent/CN112584858A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0225—Spirochetes, e.g. Treponema, Leptospira, Borrelia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/20—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Spirochaetales (O), e.g. Treponema, Leptospira
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/205—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Campylobacter (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1085—Transferases (2.) transferring alkyl or aryl groups other than methyl groups (2.5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y205/00—Transferases transferring alkyl or aryl groups, other than methyl groups (2.5)
    • C12Y205/01—Transferases transferring alkyl or aryl groups, other than methyl groups (2.5) transferring alkyl or aryl groups, other than methyl groups (2.5.1)
    • C12Y205/01009—Riboflavin synthase (2.5.1.9)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201980035045.3A 2018-04-03 2019-04-02 抗原性ospa多肽 Pending CN112584858A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862652210P 2018-04-03 2018-04-03
US62/652,210 2018-04-03
PCT/US2019/025367 WO2019195276A1 (en) 2018-04-03 2019-04-02 Antigenic ospa polypeptides

Publications (1)

Publication Number Publication Date
CN112584858A true CN112584858A (zh) 2021-03-30

Family

ID=66397424

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980035045.3A Pending CN112584858A (zh) 2018-04-03 2019-04-02 抗原性ospa多肽

Country Status (7)

Country Link
US (2) US11993636B2 (2)
EP (1) EP3773697A1 (2)
JP (2) JP2021519599A (2)
KR (1) KR20210018205A (2)
CN (1) CN112584858A (2)
CA (1) CA3095174A1 (2)
WO (1) WO2019195276A1 (2)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114736293A (zh) * 2022-06-14 2022-07-12 中国农业科学院生物技术研究所 SARS-CoV-2中和性纳米抗体、自组装铁蛋白融合纳米抗体及制备方法和应用

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110167584B (zh) * 2016-11-07 2024-06-07 威斯塔解剖学和生物学研究所 用于针对莱姆病的dna抗体构建体
CN112512566A (zh) 2018-04-03 2021-03-16 赛诺菲 抗原性爱泼斯坦-巴尔病毒多肽
BR112020019938A2 (pt) 2018-04-03 2021-01-26 Sanofi polipeptídeos antigênicos de vírus sincicial respiratório
CN112512564A (zh) 2018-04-03 2021-03-16 赛诺菲 铁蛋白蛋白
CN111217918B (zh) * 2020-03-04 2020-11-10 中山大学 一种基于2,4-二氧四氢喋啶合酶的新型冠状病毒s蛋白双区域亚单位纳米疫苗
CN111217919B (zh) * 2020-03-04 2020-12-01 中山大学 一种基于火球菌铁蛋白的新型冠状病毒s蛋白双区域亚单位纳米疫苗
WO2023044016A2 (en) * 2021-09-17 2023-03-23 Cspc Dophen Corporation Antibody immune-stimulant conjugates and use thereof
WO2023111262A1 (en) 2021-12-17 2023-06-22 Sanofi Lyme disease rna vaccine
WO2023214082A2 (en) 2022-05-06 2023-11-09 Sanofi Signal sequences for nucleic acid vaccines
IL325800A (en) * 2023-07-10 2026-03-01 Dynavax Tech Corp Lyme disease vaccines containing adjuvant and Borrelia outer protein A antigen
WO2025015077A1 (en) * 2023-07-10 2025-01-16 Dynavax Technologies Corporation Lyme disease vaccines comprising an adjuvant and borrelia outer surface protein a and c antigens

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2057536C (en) * 1990-12-21 1999-10-26 John J. Dunn Cloning and expression of borrelia lipoproteins
ATE509102T1 (de) 1994-07-15 2011-05-15 Univ Iowa Res Found Immunomodulatorische oligonukleotide
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6429199B1 (en) 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
WO1998037919A1 (en) 1997-02-28 1998-09-03 University Of Iowa Research Foundation USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE IN THE TREATMENT OF LPS-ASSOCIATED DISORDERS
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
AU7690898A (en) 1997-05-20 1998-12-11 Ottawa Civic Hospital Loeb Research Institute Vectors and methods for immunization or therapeutic protocols
ATE356630T1 (de) 1998-04-03 2007-04-15 Univ Iowa Res Found Verfahren und produkte zur stimulierung des immunsystems mittels immunotherapeutischer oligonukleotide und zytokine
WO2001075436A1 (en) 2000-04-03 2001-10-11 Board Of Trustees Of The Leland Stanford Junior University A method for protein structure alignment
WO2002016421A2 (en) * 2000-08-18 2002-02-28 Research Foundation Of The State University Of New York Altered ospa of borrelia burgdorferi
EP1504037B1 (en) * 2002-05-10 2009-12-30 New Century Pharmaceuticals, Inc. Ferritin fusion proteins for use in vaccines and other applications
US7774185B2 (en) 2004-09-14 2010-08-10 International Business Machines Corporation Protein structure alignment using cellular automata
AU2008339984A1 (en) 2007-12-21 2009-07-02 Glaxosmithkline Biologicals S.A. Vaccine
WO2009126816A1 (en) * 2008-04-09 2009-10-15 Ventria Bioscience Production of ospa for lyme disease control
CZ301541B6 (cs) * 2008-06-25 2010-04-07 Biologické centrum AV CR, v.v.i., Parazitologický ústav Feritin 2 pro imunizaci organismu proti klíštatum
EP3705133B1 (en) * 2010-05-14 2024-06-26 Baxalta Incorporated Ospa chimeras and use thereof in vaccines
EP2694109A4 (en) 2011-04-07 2015-02-18 Neotope Biosciences Ltd COMPOSITIONS AND METHODS FOR THE TREATMENT OF PROTEIN AGGREGATION DISEASES WITH IC3B DEPOSITION
EP2515112B1 (en) 2011-04-22 2015-08-12 Sysmex Corporation Method for electrochemically detecting analyte
JP5795184B2 (ja) 2011-04-22 2015-10-14 国立大学法人 奈良先端科学技術大学院大学 被検物質の電気化学的検出方法
AU2013295647B2 (en) 2012-07-26 2018-02-08 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Multimeric fusion protein vaccine and immunotherapeutic
CZ2014320A3 (cs) * 2014-05-09 2015-11-18 VÝZKUMNÝ ÚSTAV VETERINÁRNÍHO LÉKAŘSTVÍ, v.v.i. Polyepitopový antigen, vakcinační konstrukt a vakcína pro prevenci lymeské boreliózy
CA2950085A1 (en) * 2014-05-27 2015-12-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Stabilized influenza hemagglutinin stem region trimers and uses thereof
US9703095B2 (en) 2015-01-05 2017-07-11 Edward Pakhchyan Light modulator for MEMS display
WO2016138160A1 (en) * 2015-02-24 2016-09-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Middle east respiratory syndrome coronavirus immunogens, antibodies, and their use
KR20180088458A (ko) 2015-12-04 2018-08-03 다나-파버 캔서 인스티튜트 인크. 암의 치료를 위한 mica/b 알파 3 도메인의 백신접종
FI3471760T3 (fi) 2016-06-17 2025-01-27 Boehringer Ingelheim Vetmedica Gmbh Lineaarisia tai haaroittuneita polyakryylihappopolymeeriadjuvantteja käsittäviä uusia immunogeenisiä formulaatioita
UA129243C2 (uk) 2017-04-19 2025-02-26 Інстітьют Фо Рісьорч Ін Біомедцін Антитіло, що зв'язується зі спорозоїтами p. falciparum
EP3713601A4 (en) 2017-11-21 2022-03-09 Modernatx, Inc. VACCINES AGAINST EPSTEIN-BARR VIRUS

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114736293A (zh) * 2022-06-14 2022-07-12 中国农业科学院生物技术研究所 SARS-CoV-2中和性纳米抗体、自组装铁蛋白融合纳米抗体及制备方法和应用

Also Published As

Publication number Publication date
JP2024038345A (ja) 2024-03-19
JP2021519599A (ja) 2021-08-12
KR20210018205A (ko) 2021-02-17
US11993636B2 (en) 2024-05-28
EP3773697A1 (en) 2021-02-17
CA3095174A1 (en) 2019-10-10
WO2019195276A1 (en) 2019-10-10
US20210017238A1 (en) 2021-01-21
RU2020135567A (ru) 2022-05-06
US20240417432A1 (en) 2024-12-19

Similar Documents

Publication Publication Date Title
US11993636B2 (en) Antigenic OspA polypeptides
JP7719134B2 (ja) 抗原性エプスタインバーウイルスポリペプチド
US20240216497A1 (en) Ferritin Proteins
JP7614841B2 (ja) 抗原性呼吸器合胞体ウイルスポリペプチド
JP2024041980A (ja) 抗原性インフルエンザ－フェリチンポリペプチド
RU2816208C2 (ru) АНТИГЕННЫЕ ПОЛИПЕПТИДЫ НА ОСНОВЕ ПОСЛЕДОВАТЕЛЬНОСТИ OspA
RU2807992C2 (ru) Антигенные полипептиды на основе последовательности респираторно-синцитиального вируса

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination